About uBiome
uBiome was a Healthcare company based in San Francisco (United States) founded in 2012 by Zachary Apte and Jessica Richman. It provides comprehensive sequence datasets for human microbiome research and analysis. It operates on a B2B model. uBiome has raised $109.62 million across 5 funding rounds from investors including OS Fund, 8VC and Y Combinator. The company has 33 employees. Its chief executive is Jessica Richman. The company is recorded as dissolved. Its focus areas include Biotechnology, Microbiome Analysis and Data Sequencing. Its legal entity is UBIOME, INC. Its competitors include Viome, Seed, Azitra, Flore and Evvy and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
uBiome, founded in 2012 in San Francisco, United States, focuses on providing healthcare solutions, advancing biotech innovations, microbiome analysis, and data sequencing. Provides comprehensive sequence datasets for human microbiome research and analysis. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
- Headquarters San Francisco, United States
- Employees 33
- Founders Zachary Apte, Jessica Richman
- SectorsHealthcare
- Website ubiome.com
- Social X
- Legal Name Ubiome, Inc.
- Total Equity Funding$109.62M (USD)
in 5 rounds
- Latest Funding Round$83M (USD), Series C
Sep 2018
- InvestorsOS Fund
& 7 more
- Employee Count33
Funding Insights of uBiome
uBiome has successfully raised a total of $109.62M across 5 strategic funding rounds. The most recent funding activity was a Series C round of $83 million completed in September 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $109.62M
- Total Rounds 5
- Last Round Series C — $83M
- Investors Count 8
All 5 funding rounds of uBiome with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2018 | $83M | Series C | – | OS Fund | |
| Nov 2016 | $22M | Series B | – | 8VC | |
| Aug 2014 | $4.5M | Series A | – | a16z | – |
| Jun 2014 | $120,000 | Seed | – | Y Combinator | – |
| Oct 2013 | – | Seed | – | 500 Global | – |
8 investors in total: 8 institutional.
Investors in uBiome
uBiome has secured backing from 8 investors, including venture fund investors. Prominent investors backing the company include OS Fund, 8VC and Y Combinator.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage centric sector-agnostic VC firm investing in geographies such as the US | – | osfund.co | Chicago, United States | |
Venture capital firm investing in technology, life sciences, and related sectors. | – | 8vc.com | - | |
Early-stage startups are accelerated via funding and educational programs. | – | ycombinator.com | Mountain View, United States | |
Venture capital firm investing in global startups with a focus on innovation and business support. | – | dentsu-v.com | - | |
Tech-focused Early-stage centric VC Firm investing primarily in the US | – | slowventures.com | San Francisco, United States | |
Startups are accelerated by Stanford-backed program in Palo Alto. | – | startx.com | Palo Alto, United States | |
Venture capital investments in technology sectors are handled by Andreessen Horowitz. | – | a16z.com | - | |
Venture capital and acceleration are provided to tech startups. | – | 500.co | Ho Chi Minh City, Vietnam |
Investor details for uBiome
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of uBiome
6 people are tracked at uBiome (5 in leadership, 1 in board & advisors); the tracked headcount is 33.
| Name | Role | Group |
|---|---|---|
Zachary Apte | Co-Founder, CTO | Leadership |
Jessica Richman | Co-Founder, CEO | Leadership |
Robin Chiu | Interim CFO | Leadership |
Curtis Solsvig | Interim CEO | Leadership |
Karthik Bhavaraju | Interim COO | Leadership |
Zac Apte | Co-Founder | Board & advisors |
Complete people profiles for uBiome
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of uBiome
3 dated milestones of uBiome across 6 years, from founding to its latest funding, stage changes and deals.
- Founded uBiome is founded.
- Funding First funding round.
- Funding Latest funding round, Series C, of $83.0M.
Competitors of uBiome
uBiome has 9 listed competitors in our database, 9 of them funded. They include Viome, Seed, Azitra, Flore and Evvy, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| viome.com | 2016 | Los Alamos, United States | $301.57M | 136 | Machine learning-based bioinformatics solutions for health insights are provided. | |
| seed.com | 2016 | Los Angeles, United States | $40.62M | – | Synbiotics are developed for simulating the gut microbiome. | |
| azitrainc.com | 2014 | Farmington, United States | $37.4M | 17 | Microbiome-based therapeutics for skin conditions like eczema are developed. | |
| flore.com | 2016 | San Diego, United States | $21.12M | – | Customized probiotics for gut health are provided via stool analysis. | |
| evvy.com | 2002 | New York, United States | $19M | 9 | Vaginal microbiome test kits are provided through an online platform. | |
| biomesense.com | 2018 | Chicago, United States | $8.43M | 9 | AI-enabled platform for microbiome data generation and analysis is developed. | |
| cosmosid.com | 2008 | Rockville, United States | $7.32M | 31 | Next-generation sequencing technologies for microorganism detection are developed. | |
| revivemed.io | 2017 | Cambridge, United States | $1.5M | – | AI-based metabolomics platform is developed for molecular data analysis. | |
| holobiome.org | 2015 | Cambridge, United States | $15.59M | – | Microbiome-based therapeutics for nervous system disorders are developed. |
Detailed competitors of uBiome
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Microbiome Therapeutics
10 companies that operate in the same segment as uBiome (Microbiome Therapeutics), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Biosolutions and enzymes are developed for biotechnology applications across industries. | 2000 | Bags Sword, Denmark | – | – | – | |
Pendulum is focused on developing advanced probiotic solutions. | 2012 | San Francisco, California, United States | USD 109.5 M | – | 55 | |
Gut microbiome insights, analytics, tests, and therapeutics are provided. | 2019 | Singapore, Singapore | USD 10.5 M | USD 1.37 M | – | |
Microbiome-based therapeutics for skin conditions like eczema are developed. | 2014 | Farmington, United States | USD 37.4 M | – | 12 | |
Engineered microbes are developed as programmable therapeutics for metabolic disorders. | 2013 | Cambridge, Massachusetts, United States | USD 34.4 M | USD 8 K | 1 | |
Therapeutics for infectious and autoimmune diseases are developed. | 2010 | Cambridge, Massachusetts, United States | USD 470.49 M | – | 71 | |
Biological drugs for skin and mucosa wound treatment are developed. | 2016 | Uppsala, Uppsala County, Sweden | USD 4.02 M | USD 1.12 M | – | |
Microbiome-based therapeutics for gut diseases are developed. | 2017 | Edinburgh, Scotland, United Kingdom | USD 72.96 M | – | 65 | |
The gut-brain axis is explored for therapeutic and nutritional innovations. | 2014 | New York, New York, United States | USD 479 M | – | 84 | |
Microbiome therapeutics are developed to address diverse diseases. | 2010 | Cambridge, Massachusetts, United States | USD 257.13 M | USD 789 K | 103 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ubiome
Complete news archive for uBiome
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about uBiome
uBiome was founded in 2012 and raised its 1st funding round 1 year after it was founded.
uBiome is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Jessica Richman is the current CEO of uBiome. They have also founded this company.
uBiome is a funded company, having raised a total of $109.62M across 5 funding rounds to date.
uBiome has 33 employees.
uBiome, founded in 2012 in San Francisco, United States, focuses on providing healthcare solutions, advancing biotech innovations, microbiome analysis, and data sequencing. Provides comprehensive sequence datasets for human microbiome research and analysis. The company is dedicated to excellence, innovation, and customer satisfaction, ensuring sustainable practices and long-term success in its sectors.
uBiome has 8 investors. Key investors include OS Fund, 8VC, Y Combinator, Dentsu Ventures, and Slow Ventures.
uBiome operates through Ubiome, Inc..